The firm expects to receive a CE mark later this year for its RT-qPCR breast cancer recurrence assay, which characterizes epithelial CTCs by detecting cytokeratin-19 expression.
A meta-analysis showed that early circulating tumor cell dynamics were associated with overall survival using Menarini Silicon Biosystems' CellSearch assay.
Ceres plans to develop its Nanotrap technology to isolate undetectable levels of circulating tumor DNA in blood samples from non-small cell lung cancer patients.
The firm also discussed recent studies comparing its UltraSeek lung cancer assay with more established liquid biopsy tests to detect drug-resistant mutations.
The firm aims to launch an early-access program by the end of the year, followed by a second white paper before the JP Morgan Healthcare Conference in January.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.
The firm will partner with startup GeneproDx on thyroid cancer diagnostic development, while a separate agreement with Endpoint Health will entail CDx development for critical illness.
Bluestar hopes to launch a pan-cancer, DNA methylation-based liquid biopsy assay as a laboratory-developed test out of an envisioned CLIA-certified lab in San Diego.
The firm is engaged in multiple clinical validation trials and aims to raise more than $100 million to launch its Helio Liver Test in the US early next year.